Congratulations, the Deal is Done: How Will Your Partnership Actually Work

Scott Bertetti is a pharmaceutical professional with a diverse background both inside and outside of the industry. He currently serves as a member of Bayer’s oncology business development team where he manages key alliances, secures collaboration partnerships and negotiates external relationships for select assets. Prior to business development, Scott led the global brand team for Bayer’s PI3K inhibitor and was part of the core team that launched the first alpha-emitting radiotherapy in the US. Scott started his tenure at Bayer in diagnostic imaging where he oversaw Bayer’s go-to-market efforts for two MR agents and a PET tracer (for beta amyloid plaque). Before joining Bayer, Scott helped launch two consumer-finance Internet companies, focusing on product development and business development. While at First USA, he created the world’s first watch-based payment system, for which he is a patent holder. As a consultant, Scott led strategy engagements with several global pharmaceutical companies. Scott started his career in finance in the computer industry. He holds an MBA from the Tuck School and a BA from Dartmouth College.

Mary Lynne Hedley, Ph.D., is a scientist by training who brings an enterprise-wide perspective to her thinking about new company formation and advancing therapeutic discovery and development. She strives to keep patients as a gravitational center in order to achieve maximum impact for all stakeholders.

Mary Lynne is a Venture Partner at Third Rock Ventures and Senior Scientific Fellow at the Broad Institute of MIT and Harvard. Prior to that, she served as Director, President and Chief Operating Officer at TESARO, Inc., a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. TESARO was acquired by GlaxoSmithKline plc in 2019. She has extensive experience in the discovery and development of new medicines, formerly serving as Executive Vice President and Chief Scientific Officer at MGI PHARMA, Executive Vice President of Eisai Corporation of North America, and Executive Vice President of Operations, and Chief Scientific Officer of Abraxis BioScience.

She sits on the boards of Eli Lilly and Company, Helsinn Healthcare SA, Veeva Systems, Inc., Centessa Pharmaceuticals plc, Youville Assisted Living Communities, and WITH (Women Innovating Together in Healthcare). Mary Lynne received her bachelor’s degree in microbiology from Purdue University, a doctorate in molecular and cellular immunology from UT Southwestern Medical Center, and completed her postdoctoral training at Harvard University in immunology and gene regulation.

Michelle Marseglia is an audit partner at Deloitte and focuses her time in the Life Science and Biotech industry. She brings over 24 years of experience to the New England practice. During her tenure, Michelle has led audit engagements of large multi-national companies as well as early-stage biotech companies. Michelle has advised her clients as they navigate through significant events and major milestones in their lifecycles, such as initial public offerings, product launches, new collaboration arrangements, and other major transactions. Michelle is passionate about serving as a mentor to younger professionals at Deloitte and is active in recruiting new professionals to the audit practice.

Phil Tinmouth's decades of biopharmaceutical industry experience include a near 20-year career at Vertex Pharmaceuticals, where he played a key role in helping drive the company’s growth. As Vice President and Head of Business Development, Phil built a dynamic team of deal and alliance professionals that executed approximately 30 external deals and collaborations, yielding multiple clinical candidates. While at Vertex, Phil served on multiple committees and teams as the company grew from roughly 300 employees with a market cap of $800 million to well over 3,000 employees and a market cap of more than $50 billion. Prior to Vertex, Phil was a senior manager at Bain & Company in Boston where he advised pharma and biotech clients on growth strategies for over five years. Phil received his bachelor’s degree in mechanical engineering from Queen’s University in Canada, and his MBA from Harvard Business School.

John Hallinan has a background deeply rooted in life sciences, spanning more than 30 years and a broad range of strategic and operational disciplines. He most recently served as Chief Business Officer at Massachusetts Biotechnology Council (MassBio), representing the world’s premier life sciences hub, where he led efforts to catalyze early-stage innovation. He previously served as CFO for companies including Cytel, Signet Laboratories, Cambium Learning, AnVil and CambridgeSoft Corporation, accumulating considerable experience in the areas of venture financings, corporate development, technology licensing and mergers and acquisitions. He currently serves as an advisor to the Center for Clinical and Translational Science at the University of Massachusetts, the CharitéBIH Entrepreneurship Summit, the German American Business Council of Boston, and Women in the Enterprise of Science and Technology (WEST).

John is a CPA and holds a BBA from St. Bonaventure University.